In support of this idea, the presence of a frequently occurring splicing factor (SF) mutation (SRSF2P95H) or treatment with an SF3B1 inhibitor renders AML cells vulnerable to PRMT5 and/or PRMT1 inhibition [14]. This evidence concerns the gene SF3B1 and acute myeloid leukemia.